248 related articles for article (PubMed ID: 12956200)
21. Visualisation of penetration of topical antifungal drug substances through mycosis-infected nails by matrix-assisted laser desorption ionisation mass spectrometry imaging.
Endringer Pinto F; Bagger C; Kunze G; Joly-Tonetti N; Thénot JP; Osman-Ponchet H; Janfelt C
Mycoses; 2020 Aug; 63(8):869-875. PubMed ID: 32406142
[TBL] [Abstract][Full Text] [Related]
22. Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity.
Monti D; Saccomani L; Chetoni P; Burgalassi S; Senesi S; Ghelardi E; Mailland F
Br J Dermatol; 2010 Feb; 162(2):311-7. PubMed ID: 19886884
[TBL] [Abstract][Full Text] [Related]
23. Successful treatment of onychomycosis with ciclopirox nail lacquer: a case report.
Galitz J
Cutis; 2001 Aug; 68(2 Suppl):23-4. PubMed ID: 11665725
[TBL] [Abstract][Full Text] [Related]
24. Toenail onychomycosis: current and future treatment options.
Finch JJ; Warshaw EM
Dermatol Ther; 2007; 20(1):31-46. PubMed ID: 17403258
[TBL] [Abstract][Full Text] [Related]
25. A-Detail fact sheet (Canada). Ciclopirox 8% nail lacquer (Penlac).
Skin Therapy Lett; 2005 Dec-2006 Jan; 10(10):suppl 1 p.. PubMed ID: 16518906
[No Abstract] [Full Text] [Related]
26. Topical and surgical treatment of onychomycosis.
Cohen PR; Scher RK
J Am Acad Dermatol; 1994 Sep; 31(3 Pt 2):S74-7. PubMed ID: 8077513
[TBL] [Abstract][Full Text] [Related]
27. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.
Bohn M; Kraemer KT
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S57-69. PubMed ID: 11051135
[TBL] [Abstract][Full Text] [Related]
28. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent.
Subissi A; Monti D; Togni G; Mailland F
Drugs; 2010 Nov; 70(16):2133-52. PubMed ID: 20964457
[TBL] [Abstract][Full Text] [Related]
29. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis.
Avner S; Nir N; Henri T
J Dermatolog Treat; 2005; 16(5-6):327-30. PubMed ID: 16428154
[TBL] [Abstract][Full Text] [Related]
30. Comparative clinical evaluation of efficacy and safety of a formulation containing ciclopirox 8% in the form of a therapeutic nail lacquer in two different posologies for the treatment of onychomycosis of the toes.
Schalka S; Nunes S; Gomes Neto A
An Bras Dermatol; 2012; 87(1):19-25. PubMed ID: 22481647
[TBL] [Abstract][Full Text] [Related]
31. The dermatopharmacologic profile of ciclopirox 8% nail lacquer.
Bohn M; Kraemer K
J Am Podiatr Med Assoc; 2000; 90(10):491-4. PubMed ID: 11107709
[TBL] [Abstract][Full Text] [Related]
32. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States.
Gupta AK; Joseph WS
J Am Podiatr Med Assoc; 2000; 90(10):495-501. PubMed ID: 11107710
[TBL] [Abstract][Full Text] [Related]
33. Development of ciclopirox nail lacquer with enhanced permeation and retention.
Thapa RK; Choi JY; Go TG; Kang MH; Han SD; Jun JH; Son MW; Yong CS; Kim JO
Arch Pharm Res; 2016 Jul; 39(7):953-9. PubMed ID: 27306785
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years.
Sigurgeirsson B; Olafsson JH; Steinsson JT; Kerrouche N; Sidou F
J Eur Acad Dermatol Venereol; 2010 Aug; 24(8):910-5. PubMed ID: 20028447
[TBL] [Abstract][Full Text] [Related]
35. Ciclopirox nail lacquer and podiatric practice.
Gupta AK; Malkin KF
J Am Podiatr Med Assoc; 2000; 90(10):502-7. PubMed ID: 11107711
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of 5% amorolfine nail lacquer in Neoscytalidium dimidiatum onychomycosis.
Bunyaratavej S; Leeyaphan C; Rujitharanawong C; Surawan TM; Muanprasat C; Matthapan L
J Dermatolog Treat; 2016 Aug; 27(4):359-63. PubMed ID: 26471716
[TBL] [Abstract][Full Text] [Related]
37. Novel Drug Delivery Strategies for the Treatment of Onychomycosis.
Dhamoon RK; Popli H; Gupta M
Pharm Nanotechnol; 2019; 7(1):24-38. PubMed ID: 31092174
[TBL] [Abstract][Full Text] [Related]
38. Comparison of user-friendliness and treatment cost of Loceryl® vs. Ciclopoli®--a patient's perspective.
Schaller M; Braunsdorf C; Mailänder-Sanchez D; Jäckel A; Müller J; Borelli C
Mycoses; 2015 Oct; 58(10):632-6. PubMed ID: 26393437
[TBL] [Abstract][Full Text] [Related]
39. Ciclopirox delivery into the human nail plate using novel lipid diffusion enhancers.
Hafeez F; Hui X; Selner M; Rosenthal B; Maibach H
Drug Dev Ind Pharm; 2014 Jun; 40(6):838-44. PubMed ID: 23600655
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of topical resin lacquer, amorolfine and oral terbinafine for treating toenail onychomycosis: a prospective, randomized, controlled, investigator-blinded, parallel-group clinical trial.
Auvinen T; Tiihonen R; Soini M; Wangel M; Sipponen A; Jokinen JJ
Br J Dermatol; 2015 Oct; 173(4):940-8. PubMed ID: 26036329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
